Literature DB >> 23354535

Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults.

Vidya Sathyanarayanan1, Tinku Thomas, Suzanne J L Einöther, Rajendra Dobriyal, M K Joshi, Srinivasan Krishnamachari.   

Abstract

RATIONALE: A number of studies have indicated positive effects of long-term administration (3 months) of Bacopa monniera (Brahmi) on various cognitive functions especially memory and anxiety. However, inconsistent results in literature may be linked to various methodological issues.
OBJECTIVE: The present study aimed to test the chronic effects (12 weeks) of 450 mg of a B. monniera (Brahmi) extract on learning and memory, information processing and anxiety in healthy adult Indian population.
METHODS: The study design was a randomised, double-blind, placebo-controlled parallel design. Participants comprised of 72 healthy urban adults, both men and women, in the age range of 35-60 years who were educated and English speaking with basic knowledge of computers from Bangalore. The outcome measures included verbal learning and memory, inspection time, attention and interference. State and trait anxiety were additional outcome variables.
RESULTS: In the present study, there were no significant differences between the two groups on any of the cognitive measures. However, there was a trend for lower state anxiety in the B. monniera (Brahmi) group as compared to placebo group.
CONCLUSIONS: The current study attempted to determine the chronic effects of single daily dose of 450 mg of Brahmi extract on cognitive performance and anxiety in healthy adults. The results of the current study are not in agreement with findings of some of the earlier studies which have found improvement both on cognitive parameters and a reduction of anxiety scores.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354535     DOI: 10.1007/s00213-013-2978-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers.

Authors:  K Wesnes; R Anand; P Simpson; L Christmas
Journal:  J Psychopharmacol       Date:  1990-01       Impact factor: 4.153

2.  Bacopa monniera extract reduces amyloid levels in PSAPP mice.

Authors:  Leigh A Holcomb; Muralikrishnan Dhanasekaran; Angie R Hitt; Keith A Young; Mark Riggs; Bala V Manyam
Journal:  J Alzheimers Dis       Date:  2006-08       Impact factor: 4.472

3.  Antistress effects of bacosides of Bacopa monnieri: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain.

Authors:  D Kar Chowdhuri; D Parmar; P Kakkar; R Shukla; P K Seth; R C Srimal
Journal:  Phytother Res       Date:  2002-11       Impact factor: 5.878

Review 4.  The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials.

Authors:  Matthew P Pase; James Kean; Jerome Sarris; Chris Neale; Andrew B Scholey; Con Stough
Journal:  J Altern Complement Med       Date:  2012-07-02       Impact factor: 2.579

5.  A scaled version of the General Health Questionnaire.

Authors:  D P Goldberg; V F Hillier
Journal:  Psychol Med       Date:  1979-02       Impact factor: 7.723

6.  Inspection time in non-demented older adults with mild cognitive impairment.

Authors:  Kathryn R Bonney; Osvaldo P Almeida; Leon Flicker; Simon Davies; Roger Clarnette; Mike Anderson; Nicola T Lautenschlager
Journal:  Neuropsychologia       Date:  2006-01-19       Impact factor: 3.139

7.  Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial.

Authors:  Con Stough; Luke A Downey; Jenny Lloyd; Beata Silber; Stephanie Redman; Chris Hutchison; Keith Wesnes; Pradeep J Nathan
Journal:  Phytother Res       Date:  2008-12       Impact factor: 5.878

8.  Chronic effects of Brahmi (Bacopa monnieri) on human memory.

Authors:  Steven Roodenrys; Dianne Booth; Sonia Bulzomi; Andrew Phipps; Caroline Micallef; Jaclyn Smoker
Journal:  Neuropsychopharmacology       Date:  2002-08       Impact factor: 7.853

9.  Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task.

Authors:  K Wesnes; D M Warburton
Journal:  Neuropsychobiology       Date:  1983       Impact factor: 2.328

10.  Validity of the 28-item General Health Questionnaire in hospitalized gastroenterology patients.

Authors:  P L Morris; R J Goldberg
Journal:  Psychosomatics       Date:  1989       Impact factor: 2.386

View more
  4 in total

Review 1.  Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance.

Authors:  K Simon Yeung; Marisol Hernandez; Jun J Mao; Ingrid Haviland; Jyothirmai Gubili
Journal:  Phytother Res       Date:  2018-02-21       Impact factor: 5.878

2.  Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems.

Authors:  Xoan Thi Le; Hang Thi Nguyet Pham; Phuong Thi Do; Hironori Fujiwara; Ken Tanaka; Feng Li; Tai Van Nguyen; Khoi Minh Nguyen; Kinzo Matsumoto
Journal:  Neurochem Res       Date:  2013-08-15       Impact factor: 3.996

3.  The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data.

Authors:  James M Brimson; Sirikalaya Brimson; Mani Iyer Prasanth; Premrutai Thitilertdecha; Dicson Sheeja Malar; Tewin Tencomnao
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

4.  Efficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b Study.

Authors:  Sudesh Prabhakar; Venugopalan Y Vishnu; Manish Modi; Manju Mohanty; Anchal Sharma; Bikas Medhi; B R Mittal; Niranjan Khandelwal; Manoj K Goyal; Vivek Lal; Rajesh Singla; Avinash Kansal; Ajit Avasthi
Journal:  Ann Indian Acad Neurol       Date:  2020-12-18       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.